688656.SHG HOB Biotech Group Corp Ltd
- Market cap
- CNY 6.80B
- P/E
- 260.9x
- P/B
- 7.46x
- ROE
- 4.0%
- Dividend yield
- 0.31%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688656.SHG undervalued?
Graham numberThe Graham number of HOB Biotech Group Corp Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HOB Biotech Group Corp Ltd fundamental analysis
No fundamental analysis for HOB Biotech Group Corp Ltd yet.
HOB Biotech Group Corp Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is based in Suzhou, China.
Full company profileHOB Biotech Group Corp Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HOB Biotech Group Corp Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 112M | 146M | 201M | 259M | 222M | 318M | 320M | 394M | 402M | 398M | 392M |
| Gross Profit | 73.3M | 102M | 142M | 176M | 145M | 219M | 202M | 245M | 257M | 233M | 236M |
| Operating Income | 3.15M | 24.6M | 49.2M | 70.1M | 65.1M | 97.5M | 47.6M | 55.8M | 41.4M | 26.8M | 36.0M |
| EBITDA | 7.41M | 34.0M | 57.9M | 88.3M | 82.4M | 120M | 75.5M | 92.6M | 83.2M | 63.8M | 35.2M |
| Net Income | 4.34M | 21.4M | 40.2M | 63.8M | 56.6M | 86.2M | 41.7M | 47.3M | 36.8M | 23.2M | 33.4M |
| EPS | 0.10 | 0.47 | 0.88 | 1.35 | 1.20 | 1.40 | 0.66 | 0.74 | 0.58 | 0.37 | 0.53 |
| Balance Sheet | |||||||||||
| Total Assets | 125M | 144M | 225M | 283M | 296M | 864M | 945M | 949M | 1.03B | 931M | 916M |
| Total Liabilities | 67.9M | 65.2M | 92.1M | 134M | 90.0M | 93.9M | 165M | 139M | 221M | 111M | 85.2M |
| Shareholders' Equity | 56.7M | 79.0M | 133M | 150M | 206M | 770M | 780M | 811M | 812M | 820M | 831M |
| Cash & Short-term Investments | 13.0M | 14.0M | 66.5M | 90.8M | 58.8M | 455M | 289M | 163M | 122M | 63.3M | 64.9M |
| Total Debt | 37.5M | 37.0M | 19.0M | 50.1M | 44.0M | 30.9M | 65.4M | 51.1M | 115M | 46.2M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 6.42M | 22.3M | 46.5M | 68.6M | 58.2M | 105M | 58.3M | 103M | 101M | 72.9M | - |
| Capital Expenditure | 17.2M | 20.8M | 26.7M | 34.8M | 57.0M | 168M | 220M | 178M | 155M | 73.9M | 23.5M |
| Free Cash Flow | -10.7M | 1.44M | 19.9M | 33.8M | 1.21M | -63.1M | -162M | -75.3M | -54.1M | -961K | 51.0M |
| Ratios | |||||||||||
| ROE | 7.6% | 27.0% | 30.2% | 42.7% | 27.4% | 11.2% | 5.3% | 5.8% | 4.5% | 2.8% | 4.0% |
| ROA | 3.5% | 14.8% | 17.8% | 22.5% | 19.1% | 10.0% | 4.4% | 5.0% | 3.6% | 2.5% | 3.6% |
| Net Profit Margin | 3.9% | 14.6% | 19.9% | 24.6% | 25.5% | 27.1% | 13.0% | 12.0% | 9.1% | 5.8% | 8.5% |
| Debt to Equity | 0.66x | 0.47x | 0.14x | 0.33x | 0.21x | 0.04x | 0.08x | 0.06x | 0.14x | 0.06x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HOB Biotech Group Corp Ltd dividends
- Dividend yield
- 0.31%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 89.6%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.8M | 0.33 | 89.6% |
| 2024 | CNY 28.2M | 0.44 | 76.5% |
| 2023 | CNY 20.8M | 0.33 | 43.9% |
| 2022 | CNY 33.4M | 0.53 | 80.2% |
| 2021 | CNY 18.9M | 0.31 | 21.9% |
| 2020 | CNY 49.2M | 1.04 | 86.9% |
| 2019 | CNY 47.3M | 1.00 | 74.1% |
| 2018 | 1.66M | 0.04 | 4.1% |
| 2017 | 1.84M | 0.04 | 8.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns HOB Biotech Group Corp Ltd
- Insiders 77.46%
- Institutions 1.66%
- Public & others 20.88%
- Shares outstanding 63.5M
- Free float 35.6M
HOB Biotech Group Corp Ltd company profile
- Company name
- HOB Biotech Group Corp Ltd
- Ticker
- 688656.SHG
- ISIN
- CNE100004C37
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 546
- Fiscal year end
- December
- Address
- No. 9, Dongyanli Road, Suzhou, China, 215009
- Phone
- 86 512 6956 1996
- Website
- hobiotech.com
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is based in Suzhou, China.
HOB Biotech Group Corp Ltd management
4- Mr. John LiChairman & GM · born 1963
- Mr. Zhang YangqingCFO & Director · born 1968
- Ms. Aixiang XieSecretary & Director · born 1982
- Chun Li LiAccounting Supervisor